StockNow
Log in
U.S. Markets

Gilead (GILD) received a positive CHMP opinion for Trodelvy plus Keytruda as a first-line treatment for PD-L1-positive metastatic triple-negative breast cancer, with a European Commission decision expected later in 2026

StockNow breaking-news AI analysis

Gilead's Trodelvy/Keytruda combo received positive CHMP opinion for 1st-line mTNBC, following recent FDA approval. Final EC decision expected late 2026, potentially solidifying Trodelvy's 1st-line market dominance.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement

Geopolitics

The draft agreed to by Iranian and Omani negotiators awaits final approval from Iran’s supreme leader, two regional officials told The Associated Press on Wednesday

Geopolitics

Only 'one or two issues' remain unresolved in Iran-Oman talks, a senior diplomatic source tells Al Jazeera